Application of the Preclinical Alzheimer’s Cognitive Composite for tracking progression in cognitively unimpaired older adults with known Amyloid status: A 24‐month Interim Analysis of the Chariot‐Pro cohort

The ongoing CHARIOT‐PRO Substudy aims to estimate the rate of cognitive change in the early Alzheimer’s pathological continuum, comparing individuals with and without baseline biomarker evidence of amyloid deposition, over a 4.5yr follow up. We previously reported subtle cognitive differences between the two groups at baseline. Here we extend follow‐up to 24m.